Innate Pharma (NASDAQ:IPHA) Rating Lowered to Sell at Zacks Investment Research
According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “
Several other equities analysts have also weighed in on the company. SVB Leerink cut their target price on Innate Pharma from $9.00 to $7.00 and set an outperform rating on the stock in a research note on Wednesday, September 9th. ValuEngine raised Innate Pharma from a hold rating to a buy rating in a research note on Wednesday, September 9th. Finally, Bryan, Garnier & Co lowered Innate Pharma from a buy rating to a neutral rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $7.00.
About Innate Pharma
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Featured Article: Hang Seng Index (HSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.